DeepMed Research

Innovent Biologics (Suzhou) Co., Ltd

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Phase Ib/III Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above Chemotherapies

Phase 1

Completed

Conditions: Small Cell Lung Carcinoma

Interventions: Drug: paclitaxel
Drug: IBI318

First Posted Date: 2020-12-17

Last Posted Date: 2023-02-27

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 20

Registration Number: NCT04672928

Locations: 🇨🇳
Jilin Povince Cancer Hospital, Changchun, Jilin, China

A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer

Phase 1

Completed

Conditions: Advanced Lung Cancer

Interventions: Biological: IBI939
Biological: Sintilimab

First Posted Date: 2020-12-17

Last Posted Date: 2023-06-22

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 19

Registration Number: NCT04672356

Locations: 🇨🇳
Jilin Province Cancer Hospital, Jilin, China

A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC

Phase 1

Completed

Conditions: Advanced Lung Cancer

Interventions: Biological: IBI939
Biological: Sintilimab

First Posted Date: 2020-12-17

Last Posted Date: 2023-06-22

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 42

Registration Number: NCT04672369

Locations: 🇨🇳
Jilin Province Cancer Hospital, Jilin, China

A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma

Phase 1

Terminated

Conditions: Hepatocellular Carcinoma

Interventions: Procedure: cTACE
Drug: IBI318
Drug: placebo

First Posted Date: 2020-11-19

Last Posted Date: 2023-03-16

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 10

Registration Number: NCT04635527

Locations: 🇨🇳
The First Affiliated Hospital Zhejiang University, Hangzhou, Zhejiang, China

Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Phase 1

Terminated

Conditions: Advanced Cutaneous Squamous Cell Carcinoma

Interventions: Drug: IBI318

First Posted Date: 2020-11-02

Last Posted Date: 2023-03-28

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 15

Registration Number: NCT04611321

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, China

Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma (Nasal Type) Trial

Phase 1

Terminated

Conditions: Extranodal NK/T Cell Lymphoma, Nasal Type

Interventions: Drug: IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody)

First Posted Date: 2020-10-26

Last Posted Date: 2023-03-15

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 9

Registration Number: NCT04602065

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangdong, China

A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy

Phase 2

Completed

Conditions: Advanced Cervical Cancer

Interventions: Drug: IBI310
Drug: Placebo
Drug: Sintilimab

First Posted Date: 2020-10-19

Last Posted Date: 2023-12-18

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 205

Registration Number: NCT04590599

Locations: 🇨🇳
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital）, Zhenjiang, China
🇨🇳
Innovent Biologics, Inc., Suzhou, Jiangsu, China

Single Dose Tolerability and Pharmacokinetics of IBI112 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: IBI112 dose3
Drug: IBI112 dose5
Drug: IBI112 dose2
Drug: IBI112 dose7
Drug: IBI112 dose1
Drug: IBI112 dose4
Drug: IBI112 dose6

First Posted Date: 2020-08-13

Last Posted Date: 2022-09-19

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 46

Registration Number: NCT04511624

Locations: 🇨🇳
Huashan Hospital Affiliated to Fudan University, Shanghai, China

A Study Evaluating the Safety and Efficacy of IBI188 in Combination With AZA in Subjects With Newly Diagnosed MDS

Phase 1

Suspended

Conditions: MDS

Interventions: Drug: IBI188
Drug: Azacitidine

First Posted Date: 2020-08-13

Last Posted Date: 2020-12-21

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 32

Registration Number: NCT04511975

Locations: 🇺🇸
Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸
American Oncology Partners of Maryland, PA, Bethesda, Maryland, United States
🇺🇸
New Jersey Center for Cancer Research, Brick, New Jersey, United States

Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS

Phase 1

Suspended

Conditions: Myelodysplastic Syndromes

Interventions: Drug: IBI188+azacitidine

First Posted Date: 2020-07-24

Last Posted Date: 2023-02-16

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 120

Registration Number: NCT04485065

Locations: 🇨🇳
Blood Diseases Hospital Chinese Academy Of Medical Science, Tianjin, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy